Raise closed, search for fresh raises on Seedstage

Allendale, NJ

Scaling cutting-edge orthopedic technology to improve patient outcomes.

• Innovative Biomaterial: Citregen is a citrate-based polymer that promotes natural tissue healing.
• FDA-Cleared Products: The company has secured FDA clearance for multiple products, with more launches planned.
• Strategic Partnerships: Trusted by industry leaders like Stryker Corporation for distribution and validation.
• Market Expansion: Plans to scale from 8,000 to over 80,000 patients in a $10 billion market.
• Direct Sales Channel: Launching a direct sales channel to increase margins and market penetration.

Acuitive Technologies is expanding its reach in the orthopedic biomaterials market with its innovative Citregen technology. Citregen is a family of FDA-cleared synthetic devices designed to promote tissue regeneration by increasing cell energy. Unlike traditional implants that may cause chronic inflammation, Citregen releases citrate, a natural energy source for cells, to enable natural tissue healing. The company has already achieved significant traction with over 8,000 successful implants and is trusted by industry leaders such as Stryker Corporation.

Acuitive Technologies plans to scale its operations by launching six additional FDA-cleared products between 2025 and 2026. The company aims to expand its patient base from 8,000 to over 80,000, addressing a growing $10 billion orthopedic biomaterials market. By leveraging strategic partnerships and a direct sales channel, Acuitive Technologies seeks to improve patient outcomes and reduce failure rates in procedures such as rotator cuff repairs and ACL reconstructions. The company’s approach offers a promising alternative to traditional implants, with the potential to capture significant market share in the orthopedic industry.

Company Info

Acuitive Technologies develops Citregen, a biomaterial for orthopedic surgery that promotes tissue regeneration and reduces inflammation.

Acuitive Technologies focuses on advancing orthopedic surgery through its innovative biomaterial, Citregen. This FDA-cleared family of synthetic devices is designed to promote tissue regeneration by increasing cell energy, offering a solution to the common issues associated with traditional implants, such as chronic inflammation and scar tissue formation. Citregen releases citrate, a natural energy source for cells, which aids in natural tissue healing. The company has already achieved significant traction with over 8,000 devices implanted and plans to expand its product line with six more FDA-cleared products by 2025-2026.

Acuitive Technologies operates in the growing orthopedic biomaterials market, which is valued at over $10 billion. The company collaborates with industry leaders like Stryker Corporation to distribute its products, aiming to expand its reach from 8,000 to over 80,000 patients. By focusing on solutions that improve patient outcomes and reduce the need for revision surgeries, Acuitive is positioned to address high-failure procedures such as rotator cuff repairs and ACL reconstructions, ultimately reshaping the future of orthopedic medicine.